PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
24464600-0	2014	CYP2C9*2 allele increases risk for hypoglycemia in POR*1/*1 type 2 diabetic patients treated with sulfonylureas.	Sulfonylurea Compounds	98-111	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	0-6	
24464600-1	2014	It is previously shown that carriers of the defective allele CYP2C9*3 that leads to impaired sulfonylurea metabolism are at increased sulfonylurea-induced hypoglycemia risk due to diminished drug metabolism, whereas no effect of CYP2C9*2 allele was found.	Sulfonylurea Compounds	93-105	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	61-67	
24464600-8	2014	In a model adjusted for age, BMI, duration of T2DM and renal function, and POR*1/*1 entered as a selection variable, CYP2C9*2 allele increased the hypoglycemia risk in response to sulfonylurea (odds ratio: 3.218, p=0.031).	Sulfonylurea Compounds	180-192	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	117-123	
24464600-9	2014	In conclusion, our results suggest that POR*28 allele is masking the association of CYP2C9*2 allele with sulfonyl-urea-induced hypoglycemia.	Sulfonylurea Compounds	105-118	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	84-90	
24464600-10	2014	Therefore, POR*28 allele is an important source of CYP2C9 activity variability and combined with CYP2C9 gene poly-morphisms may explain individual variability in the effect of sulfonylureas.	Sulfonylurea Compounds	176-189	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	97-103